 |
Company |
 Farsight Bioscience wins Biotechnology Company Of The Year Award for Western Europe 2011. Click here to watch the video interview with our Chief Executive Officer, Erling Refsum.
Farsight Bioscience’s focus is on developing drugs in large markets with significant growth that offer the potential to become blockbusters. Its focus is on primary care drugs for the prevention and treatment of human diseases. Farsight Bioscience has identified three indication areas that satisfy these criteria:
- Metabolic Disorders (Obesity and Diabetes-2),
- Inflammatory diseases (arthritis, bowel diseases),
- Cardiovascular (anti-atherosclerotic and anti-inflammatory)
Farsight Bioscience runs a lean as well as cost- and time-efficient drug development engine through the use of outsourcing and strategic partnerships. The Company’s objective is to exit any research project as soon as a commercially viable exit can be found. Also, the Company intends to collaborate with other biotech entities to share research and cost. Farsight Bioscience aims to create value through being cost- and time-efficient as well as industrious and systematic, operating on the prime spot of value creation between drug discovery and phase III clinical studies.
The Company’s mission is to make safe and effective drugs available to the public, quickly and at affordable prices.
|
|
|
 |
